← Back to Search

BTK Inhibitor

Ibrutinib + Pembrolizumab for Leukemia and Lymphoma

Phase 1 & 2
Recruiting
Led By Joshua Brody, MD
Research Sponsored by Joshua Brody
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Male subjects of childbearing potential must agree to use adequate contraception from the first dose of study therapy through 120 days after the last dose
Have a performance status of 0 or 1 on the ECOG Performance Scale
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 1 year
Awards & highlights

Study Summary

This trial will help determine the best dose of ibrutinib in combination with pembrolizumab for patients with CLL or MCL that has relapsed or progressed after prior therapy. The safety of this combination will also be studied.

Who is the study for?
Adults over 18 with chronic lymphocytic leukemia (CLL) or mantle cell lymphoma (MCL) who can provide consent and have measurable disease. They must be in good health otherwise, not pregnant, agree to use contraception, and haven't used certain other treatments recently like immunosuppressives or live vaccines.Check my eligibility
What is being tested?
The trial is testing a combination of two drugs: Ibrutinib, which blocks an enzyme that helps blood cancer cells grow; and Pembrolizumab, an antibody designed to help the immune system fight tumor cells. This study aims to find the right dose and see if this experimental combo works for CLL/MCL.See study design
What are the potential side effects?
Possible side effects include reactions related to the immune system attacking normal organs (autoimmune reactions), infusion-related reactions from receiving the drug into a vein, fatigue, infections due to lowered immunity, liver problems, and possibly others as it's an experimental treatment.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am a man who can father a child and will use birth control during and for 4 months after the study.
Select...
I am fully active or restricted in physically strenuous activity but can do light work.
Select...
I am 18 years old or older.
Select...
My recent tests show my organs are functioning well.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Dose Limiting Toxicity (DLT)
Secondary outcome measures
Complete Response (CR) rate
Overall Survival Rate
Progression-free Survival Rate

Side effects data

From 2024 Phase 2 trial • 57 Patients • NCT03004183
21%
Fatigue
13%
Nausea
11%
Back pain
9%
Shortness of Breath
9%
Anemia
9%
Abdominal pain
9%
Diarrhea
7%
Pneumonia
7%
Kidney Injury and/or Infection
7%
Dyspnea
7%
Weight Loss
5%
Malnutrition, Hypercalcemia and Weakness
5%
Pneumothorax
5%
Intractable pain, back pain, hip pain
5%
Activated partial thromboplastin time prolonged
4%
Pleural effusion
4%
Atrial fibrillation with rapid ventricular response
2%
Thrombocytopenia
2%
Respiratory failure
2%
Skin rash
2%
colitis
100%
80%
60%
40%
20%
0%
Study treatment Arm
Single Arm

Trial Design

2Treatment groups
Experimental Treatment
Group I: Participants with MCLExperimental Treatment2 Interventions
Participants with relapsed/ refractory Mantle Cell Lymphoma (MCL)
Group II: Participants with CLLExperimental Treatment2 Interventions
Participants with relapsed/ refractory Chronic Lymphocytic Leukemia (CLL) or 17p- CLL
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Ibrutinib
FDA approved
Pembrolizumab
FDA approved

Find a Location

Who is running the clinical trial?

Joshua BrodyLead Sponsor
1 Previous Clinical Trials
21 Total Patients Enrolled
Merck Sharp & Dohme LLCIndustry Sponsor
3,886 Previous Clinical Trials
5,054,532 Total Patients Enrolled
Joshua Brody, MD5.03 ReviewsPrincipal Investigator - Icahn School of Medicine at Mount Sinai
Icahn School of Medicine at Mount Sinai
3 Previous Clinical Trials
83 Total Patients Enrolled

Media Library

Ibrutinib (BTK Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT03153202 — Phase 1 & 2
Chronic Lymphocytic Leukemia Research Study Groups: Participants with MCL, Participants with CLL
Chronic Lymphocytic Leukemia Clinical Trial 2023: Ibrutinib Highlights & Side Effects. Trial Name: NCT03153202 — Phase 1 & 2
Ibrutinib (BTK Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03153202 — Phase 1 & 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are you looking for more test subjects at the moment?

"Yes, this study is still open to new participants according to the clinicaltrials.gov listing. This trial was originally posted on July 14th, 2017 and updated last on August 22nd, 2022."

Answered by AI

Does this research pertain to middle-aged adults?

"According to the eligibility criteria for this trial, the minimum age for enrollment is 18 and the maximum age is 99."

Answered by AI

Who can sign up for this experiment?

"This trial is looking for 40 individuals who have leukemia or lymphoid and meet the following requirements: be willing to provide a tissue sample from a recent biopsy, be of age 18 or older, have a performance status of 0 or 1 on the ECOG Performance Scale, demonstrate adequate organ function, use contraception if of childbearing potential, and abstain from sexual activity if this is their usual lifestyle."

Answered by AI

What therapeutic benefits has Pembrolizumab been shown to provide?

"Pembrolizumab can be used as part of a treatment plan for patients with malignant neoplasms, unresectable melanoma, and microsatellite instability high."

Answered by AI

What other research has been conducted with Pembrolizumab?

"There are a total of 1153 clinical trials currently underway that involve Pembrolizumab. Of these, 145 have reached Phase 3. The majority of research is based in Houston, Texas; however, there are 43,225 locations running Pembrolizumab trials globally."

Answered by AI

How many test subjects are part of this experiment?

"That is correct. The website clinicaltrials.gov has the most recent information on this study, which was updated on 8/22/2022. This trial posted on 7/14/2017 and is looking for 40 patients that meet the qualifications from 1 location."

Answered by AI
~4 spots leftby Dec 2025